Rhythm Pharmaceuticals (RYTM) Financials: History & Chart

Rhythm Pharmaceuticals, Inc.(RYTM)

Biotechnology · Boston, MA

$90.77-1.68 (-1.82%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

Boston, MA

414 employees

www.rhythmtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: David Meeker

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	239.92M	71.25M	60.11M	57.25M	51.30M	48.50M	32.70M	41.83M	33.25M
Cost of Goods Sold	26.39M	8.93M	7.16M	4.80M	5.50M	5.54M	3.65M	3.79M	3.83M
Gross Profit	213.53M	62.32M	52.95M	52.45M	45.80M	42.96M	29.06M	38.04M	29.42M
Gross Profit Margin	89.0%	87.5%	88.1%	91.6%	89.3%	88.6%	88.8%	90.9%	88.5%
Total Operating Expenses	414.16M	110.88M	105.32M	99.51M	98.45M	88.25M	76.06M	79.30M	73.31M
Research & Development	173.21M	43.43M	41.73M	42.03M	46.03M	42.31M	36.97M	41.17M	37.93M
Selling, General & Administrative	240.95M	67.45M	63.59M	57.48M	52.43M	45.95M	39.09M	38.13M	35.38M
Operating Income (EBIT)	-200.63M	-48.55M	-52.36M	-47.06M	-52.65M	-45.30M	-47.00M	-41.26M	-43.88M
Operating Margin	-83.6%	-68.1%	-87.1%	-82.2%	-102.6%	-93.4%	-143.7%	-98.6%	-132.0%
Income Before Tax (EBT)	-204.28M	-48.85M	-55.09M	-47.54M	-52.79M	-46.30M	-49.42M	-43.38M	-43.98M
Interest Income	15.19M	3.22M	3.55M	4.08M	4.33M	3.24M	3.64M	3.52M	4.05M
Interest Expense	18.48M	4.54M	4.58M	4.62M	4.74M	5.82M	5.41M	5.45M	5.24M
Other Income/Expense	-3.65M	-302K	-2.73M	-473K	-140K	-999K	-2.41M	-2.13M	-100K
Net Income	-205.35M	-49.30M	-55.64M	-47.51M	-52.90M	-46.63M	-49.50M	-43.29M	-43.64M
Income Tax Expense	1.07M	444K	545K	-31K	111K	337K	80K	-90K	-344K
Net Profit Margin	-85.6%	-69.2%	-92.6%	-83.0%	-103.1%	-96.1%	-151.4%	-103.5%	-131.2%
EBITDA	-199.55M	-48.30M	-52.11M	-46.79M	-52.35M	-44.92M	-46.62M	-40.87M	-43.50M
EBITDA Margin	-83.2%	-67.8%	-86.7%	-81.7%	-102.0%	-92.6%	-142.6%	-97.7%	-130.8%
Depreciation & Amortization	1.08M	251K	252K	272K	304K	379K	383K	383K	385K
EPS Basic	-3.11	-0.73	-0.83	-0.73	-0.82	-0.75	-0.81	-0.72	-0.71
EPS Diluted	-3.11	-0.73	-0.83	-0.73	-0.82	-0.75	-0.81	-0.72	-0.71
Weighted Average Basic Shares	68.59M	68.59M	67.97M	66.88M	64.35M	63.68M	63.06M	61.60M	61.22M
Weighted Average Diluted Shares	68.59M	68.59M	67.97M	66.88M	64.35M	63.68M	63.06M	61.60M	61.22M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	189.76M	130.13M	77.43M	23.64M	3.15M	0.00	0.00	0.00
Cost of Goods Sold	19.49M	13.37M	9.30M	2.13M	599K	690K	834K	442K
Gross Profit	170.26M	116.76M	68.13M	21.50M	2.56M	-690K	-834K	-442K
Gross Profit Margin	89.7%	89.7%	88.0%	91.0%	81.0%	N/A	N/A	N/A
Total Operating Expenses	362.28M	382.26M	252.48M	200.66M	172.61M	135.88M	145.17M	78.42M
Research & Development	167.34M	237.96M	134.95M	108.63M	104.13M	90.45M	109.45M	50.34M
Selling, General & Administrative	194.94M	144.30M	117.53M	92.03M	68.49M	46.13M	36.55M	28.08M
Operating Income (EBIT)	-192.02M	-265.50M	-184.36M	-179.16M	-170.06M	-136.57M	-146.00M	-78.42M
Operating Margin	-101.2%	-204.0%	-238.1%	-757.9%	-5391.9%	N/A	N/A	N/A
Income Before Tax (EBT)	-196.04M	-260.26M	-184.11M	-181.12M	-69.61M	-134.00M	-140.73M	-74.06M
Interest Income	15.29M	14.71M	13.95M	4.03M	447K	2.58M	5.27M	4.35M
Interest Expense	20.58M	20.60M	13.89M	5.20M	N/A	N/A	N/A	N/A
Other Income/Expense	-4.03M	5.25M	243K	-1.96M	100.45M	2.58M	5.27M	4.35M
Net Income	-196.54M	-260.60M	-184.68M	-181.12M	-69.61M	-130.73M	-134.62M	-74.06M
Income Tax Expense	497K	346K	564K	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-103.6%	-200.3%	-238.5%	-766.2%	-2207.1%	N/A	N/A	N/A
EBITDA	-190.68M	-263.94M	-182.60M	-177.49M	-168.90M	-135.88M	-145.17M	-77.97M
EBITDA Margin	-100.5%	-202.8%	-235.8%	-750.8%	-5355.1%	N/A	N/A	N/A
Depreciation & Amortization	1.34M	1.56M	1.76M	1.67M	1.16M	690K	834K	442K
EPS Basic	-3.11	-4.34	-3.20	-3.51	-1.37	-2.96	-3.70	-2.39
EPS Diluted	-3.11	-4.34	-3.20	-3.51	-1.37	-2.96	-3.70	-2.39
Weighted Average Basic Shares	64.98M	60.99M	57.67M	52.12M	49.60M	44.13M	36.42M	31.00M
Weighted Average Diluted Shares	64.98M	60.99M	57.67M	52.12M	49.60M	44.13M	36.42M	31.00M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.